EBIT: Income before interest and taxes.
Verve Therapeutics, Inc. (VERV) had EBIT of $-228.66M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$32.33M |
|
$-198.71M |
|
-- |
|
$32.33M |
|
$260.99M |
|
$-228.66M |
|
$30.30M |
|
$-198.36M |
|
$-198.36M |
|
$-198.71M |
|
$-198.71M |
|
$-198.71M |
|
$-198.71M |
|
|
EBIT |
$-228.66M |
$-234.31M |
|
84.72M |
|
84.72M |
|
$-2.35 |
|
$-2.35 |
|
| Balance Sheet Financials | |
$542.75M |
|
$18.64M |
|
$104.64M |
|
$647.39M |
|
$42.91M |
|
-- |
|
$111.08M |
|
$153.99M |
|
$493.40M |
|
$493.40M |
|
$493.40M |
|
88.76M |
|
| Cash Flow Statement Financials | |
$-157.69M |
|
$74.88M |
|
$49.20M |
|
$210.95M |
|
$177.33M |
|
$-33.62M |
|
$43.26M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.65 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-707.23% |
|
-707.23% |
|
-724.71% |
|
-613.51% |
|
-614.59% |
|
$-161.43M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
9.93 |
|
36.75 |
|
-40.27% |
|
-40.27% |
|
-30.69% |
|
-40.27% |
|
$5.56 |
|
$-1.91 |
|
$-1.86 |
|